Literature DB >> 9353398

Nicotinic-receptor mediation of S(-)nornicotine-evoked -3H-overflow from rat striatal slices preloaded with -3H-dopamine.

L Teng1, P A Crooks, S T Buxton, L P Dwoskin.   

Abstract

Previous results from our laboratory demonstrated that S(-)nornicotine, a major tobacco alkaloid and an active nicotine metabolite present in the CNS, increases dopamine release from rat striatal slices in a concentration-dependent and calcium-dependent manner. The present study determined if S(-)nornicotine-evoked dopamine release was the result of nicotinic receptor stimulation. Stereoselectivity and the ability of classical noncompetitive and competitive nicotinic receptor antagonists (mecamylamine (MEC) and dihydro-beta-erythroidine (DHbetaE), respectively) to inhibit S(-)nornicotine-evoked [3H]overflow from [3H]dopamine-preloaded rat striatal slices were investigated. Nornicotine increased [3H]overflow in a stereoselective manner at concentrations from 1 to 100 microM. MEC (0.01-100 microM) or DHbetaE (0.01-10 microM) alone did not evoke -3H-overflow. However, 100 microM DHbetaE evoked -3H-overflow, and therefore, was not used in experiments investigating antagonism of S(-)nornicotine's effect. MEC and DHbetaE inhibited S(-)nicotine- (10 microM) evoked [3H]overflow in a concentration-dependent manner. Concentrations of MEC (100 microM) and DHbetaE (10 microM) which maximally inhibited S(-)nicotine's effect were chosen for subsequent experiments determining inhibition of the effect of S(-)nornicotine (0.1 microM-3 mM). MEC and DHbetaE significantly inhibited the effect of low concentrations (<100 microM) of S(-)nornicotine; however, higher concentrations (>100 microM) of S(-)nornicotine were not inhibited by either nicotinic antagonist. Taken together, the results suggest that low concentrations of S(-)nornicotine stimulate nicotinic receptors to evoke the release of dopamine from dopaminergic presynaptic terminals. Thus, nornicotine, which acts as an agonist at neuronal nicotinic receptors, may contribute to the neuropharmacological effects of nicotine and tobacco use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353398

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Authors:  Paula L Vieira-Brock; Eleanor I Miller; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-18       Impact factor: 3.205

2.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

3.  A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasine, and anatabine.

Authors:  Joshua T Ayers; Rui Xu; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2005-10-31       Impact factor: 4.009

4.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

5.  Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats.

Authors:  Rajeev I Desai; David J Barber; Philip Terry
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

6.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

7.  Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity.

Authors:  Sangeetha P Sumithran; Peter A Crooks; Rui Xu; Jun Zhu; Agripina G Deaciuc; Lincoln H Wilkins; Linda P Dwoskin
Journal:  AAPS J       Date:  2005-08-29       Impact factor: 4.009

8.  Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats.

Authors:  Emily M Jutkiewicz; Danielle M Nicolazzo; Myung N Kim; Margaret E Gnegy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

9.  Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Authors:  M L Gregório; E C Wietzikoski; M M Ferro; J L M Silveira; M A B F Vital; C Da Cunha
Journal:  Neurotox Res       Date:  2009-03-18       Impact factor: 3.911

10.  Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Guangrong Zheng; Sangeetha P Sumithran; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.